Why the study?
Dual antiplatelet therapy is standard after PCI, but the optimal duration remains a topic of ongoing debate.
Does ultrashort dual antiplatelet therapy (≤1 month) reduce net adverse clinical events compared to standard dual antiplatelet therapy (≥6 months) in patients undergoing percutaneous coronary intervention?
Does ultrashort dual antiplatelet therapy (≤1 month) reduce net adverse clinical events compared to standard dual antiplatelet therapy (≥6 months) in patients undergoing percutaneous coronary intervention?
An ultrashort dual antiplatelet therapy strategy of 1 month or less followed by single antiplatelet therapy reduces bleeding and net adverse clinical events without increasing ischemic risk compared to standard DAPT of 6 months or more after PCI.
Answers are grounded in this paper and cite their sources.
Supports ultrashort DAPT post-PCI to reduce NACE and bleeding without ischemic trade-off; extends RCT evidence via aggregated safety data.
Background: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor antagonist is the standard antithrombotic therapy after percutaneous coronary intervention (PCI); however, the optimal duration of this treatment remains a topic of ongoing debate. This study aimed to assess the clinical utility of an ultrashort dual antiplatelet therapy (US-DAPT) regimen (≤1 month) compared with standard DAPT (≥6 months) after PCI. In addition, the outcomes of choosing single antiplatelet therapy after US-DAPT, either clopidogrel or ticagrelor, were also analyzed. Methods: We queried MEDLINE, Cochrane Central Registry of Controlled Trials, Embase, and ClinicalTrials.gov databases from their commencement to May 2024 for all randomized controlled trials (RCTs) that directly compared US-DAPT (≤1 month) with standard therapy (≥6 months). The primary end point was net adverse clinical events (NACE), defined as a composite of major adverse cardiovascular or cerebrovascular events (MACCE) and clinically relevant bleeding (CRB). Results: = 41%) However, no significant difference in MACCE, all-cause mortality, cardiovascular disease-related deaths, MI, stroke, MI, TVR, and ST was observed. Conclusions: In patients undergoing PCI, US-DAPT was associated with lower NACEs and bleeding risk without increasing the occurrence of ischemic events, including ST and MI, when compared with at least 6 months of DAPT, irrespective of the choice of single antiplatelet therapy, whether clopidogrel or ticagrelor, following DAPT.
No takes yet. Share an insight, caveat, or question.
Dodoo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: